PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31118272-0	2019	Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.	nintedanib	87-97	ret proto-oncogene	Homo sapiens	41-44	
31118272-4	2019	Nintedanib is a RET TKI that inhibits the vandetanib-resistant RET(G810A) mutant.	nintedanib	0-10	ret proto-oncogene	Homo sapiens	16-19	
31118272-4	2019	Nintedanib is a RET TKI that inhibits the vandetanib-resistant RET(G810A) mutant.	nintedanib	0-10	ret proto-oncogene	Homo sapiens	63-66	
31118272-5	2019	Here, we determined the X-ray co-crystal structure of RET kinase domain-nintedanib complex to 1.87 A resolution and a RET(G810A) kinase domain crystal structure to 1.99 A resolution.	nintedanib	72-82	ret proto-oncogene	Homo sapiens	54-57	
31118272-7	2019	Drug-sensitivity profiling of RET(L881V) revealed that it remains sensitive to nintedanib.	nintedanib	79-89	ret proto-oncogene	Homo sapiens	30-33	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	8-18	ret proto-oncogene	Homo sapiens	4-7	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	8-18	ret proto-oncogene	Homo sapiens	66-69	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	157-167	ret proto-oncogene	Homo sapiens	4-7	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	157-167	ret proto-oncogene	Homo sapiens	66-69	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	157-167	ret proto-oncogene	Homo sapiens	4-7	
31118272-8	2019	The RET-nintedanib co-crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperazine, anilino, and phenyl groups of nintedanib, providing a structural basis for explaining that the p.L730V mutation identified in nine independently isolated cell lines resistant to nintedanib.	nintedanib	157-167	ret proto-oncogene	Homo sapiens	66-69	
31118272-9	2019	Comparisons of RET-nintedanib, RET(G810A), and RET-vandetanib crystal structures suggested that the solvent-front Ala-810 makes hydrophobic contacts with a methyl group and aniline in nintedanib and blocks water access to two oxygen atoms of vandetanib, resulting in an energetic penalty for burying polar groups.	nintedanib	19-29	ret proto-oncogene	Homo sapiens	15-18	
31118272-10	2019	Of note, even though the p.L881V mutation did not affect sensitivity to nintedanib, RET(L881V) was resistant to nintedanib analogs lacking a phenyl group.	nintedanib	112-122	ret proto-oncogene	Homo sapiens	84-87	
31118272-11	2019	These results provide structural insights into resistance of RET mutants against the TKIs nintedanib and vandetanib.	nintedanib	90-100	ret proto-oncogene	Homo sapiens	61-64